Amgen

From Vero - Wikipedia
Jump to navigation Jump to search

Template:Short description Template:Use mdy dates Template:Infobox company Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.

The company's major products are Prolia and XGEVA (Denosumab) for treatment of osteoporosis and bone diseases ($6.7 billion in total 2024 revenues), Enbrel (Etanercept) for treatment of autoimmune diseases ($3.3 billion in 2024 revenues), Repatha (evolocumab) for treatment of hyperlipidemia ($2.3 billion in 2024 revenues), Otezla (apremilast) for treatment of psoriasis and psoriatic arthritis ($2.1 billion in 2024 revenues), Tepezza (teprotumumab) to treat Graves' ophthalmopathy ($1.8 billion in 2024 revenues), Evenity (romosozumab) to treat osteoporosis ($1.5 billion in 2024 revenues), Kyprolis (carfilzomib) to treat cancer ($1.5 billion in 2024 revenues), Nplate (romiplostim) to regulate platelet production ($1.4 billion in 2024 revenues), and Aranesp (darbepoetin alfa) to stimulate erythropoiesis ($1.3 billion in 2024 revenues).<ref name=10K/>

Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.<ref>Template:Cite web</ref>

The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.<ref name=10K/>

The company is ranked 134th on the Fortune 500<ref>Template:Cite web</ref> and 202nd on the Forbes Global 2000.<ref>Template:Cite web</ref>

History

File:AMGenelogo.jpg
AMGen corporate logo, 1983
File:Macri Amgen.jpg
Argentine president Mauricio Macri meets with heads of Amgen, in 2018.

In April 1980, Amgen was founded in Thousand Oaks as Applied Molecular Genetics.<ref>Template:Cite news</ref> Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin.<ref name="Walsh">Template:Cite web</ref>

Its initial scientific advisory board consisted of Norman Davidson, Leroy Hood, Arnold Berk, John Carbon, Robert Schimke, Arno Motulsky, Marvin H. Caruthers, and Dave Gibson.<ref>Template:Cite journal</ref> In October 1980, Amgen named George Rathmann its first president and chief executive officer.<ref name="Walsh" /><ref>Template:Cite news</ref>

On June 17, 1983, Amgen became a public company via an initial public offering, selling two million common shares and raising nearly $40 million.<ref>Template:Cite web</ref><ref>Template:Cite news</ref><ref>Template:Cite news</ref> That same year, after more than two years of work, an Amgen research team led by Fu-Kuen Lin found and cloned the erythropoietin gene, a protein created in the kidney that stimulates red blood cell production. Lin's team created what would become Epogen (epoetin alfa).<ref>Template:Cite news</ref><ref name="Kim">Template:Cite book</ref>

In June 1984, Amgen and Kirin formed a joint venture giving Kirin the rights to Epogen in Japan.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> A year later, Amgen researcher Larry Souza and his team cloned granulocyte colony-stimulating factor (G-CSF), leading to the development of Neupogen (filgrastim).<ref name="Kim" /><ref>Template:Cite news</ref><ref>Template:Cite journal</ref>

In October 1988, Gordon Binder was named CEO, succeeding George Rathmann.<ref>Template:Cite news</ref> The following year, in 1989, Amgen received approval for the first recombinant human erythropoetin product, Epogen (epoetin alfa).<ref>Template:Cite news</ref>

In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.<ref>Template:Cite news</ref>

Amgen opened a new manufacturing facility in Puerto Rico, in March 1993, which later became the company's flagship manufacturing site.<ref>Template:Cite news</ref>

In 1994, Amgen became the fifth company to receive the National Medal of Technology and Innovation from the United States Department of Commerce, in recognition of its work developing medicines to improve quality of life for kidney and cancer patients.<ref>Template:Cite news</ref> Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp (darbepoetin alfa).<ref>Template:Cite news</ref>

2000–2014

Binder was succeeded as CEO by Kevin W. Sharer in 2000.<ref>Template:Cite news</ref> Robert A. Bradway became Amgen's president and chief executive officer in May 2012, following Sharer's retirement.<ref>Template:Cite press release</ref>

In June 2010, Amgen received approval by the Food and Drug Administration for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.<ref>Template:Cite web</ref> In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.<ref>Template:Cite web</ref> In November 2010, the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.<ref>Template:Cite press release</ref> The clinical trials primarily enrolled patients with breast or prostate cancer.

In March 2011, Amgen acquired a manufacturing facility near Dublin, Ireland.<ref>Template:Cite news</ref>

Amgen opened an affiliate in China in 2013.<ref>Template:Cite news</ref><ref>Template:Cite news</ref>

In November 2014, the company halted all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.<ref>Template:Cite web</ref> Also in November 2014, the company, in conjunction with AstraZeneca, reported positive results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.<ref>Template:Cite news</ref> In the same month, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore.<ref>Template:Cite news</ref> Blincyto (blinatumomab) was approved by the FDA in December of that year.<ref>Template:Cite journal</ref><ref>Template:Cite news</ref>

2015–2020

In March 2015, the company announced that it would license its Phase II candidate drug AMG 714 to Celimmune, which will develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.<ref>Template:Cite news</ref> In August 2015, Repatha (evolocumab) was approved by the FDA.<ref>Template:Cite news</ref>

In September 2016, the company announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.<ref>Template:Cite news</ref> Also in September, the FDA approved Amjevita (adalimumab-atto).<ref name="Staton">Template:Cite news</ref> The FDA approved Parsabiv in February 2017<ref>Template:Cite news</ref> and Mvasi (bevacizumab-awwb) in September.<ref name="Mvasi approval">Template:Cite web</ref>

In July 2018, Amgen began constructing a biomanufacturing plant at its campus in West Greenwich, Rhode Island.<ref>Template:Cite news</ref><ref>Template:Cite news</ref>

In January 2019, Evenity (romosozumab) received approval in Japan,<ref>Template:Cite web</ref><ref>Template:Cite news</ref> followed by FDA approval in April.<ref>Template:Cite news</ref> In June, Kanjinti (trastuzumab-anns) was approved by the FDA.<ref name="Kanjinti approval">Template:Cite web</ref>

In December 2019, the FDA approved Avsola (infliximab-axxq).<ref>Template:Cite news</ref>

In September 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation.<ref>Template:Cite news</ref>

In April 2020, Amgen established Amgen K.K. as the company's wholly owned affiliate in Japan.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> The company announced in July that the United States Court of Appeals for the Federal Circuit had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by the United States District Court for the District of New Jersey and rejected Sandoz's attempt to invalidate the patents on Enbrel.<ref>Template:Cite news</ref>

In August 2020, Amgen, Takeda Pharmaceutical Company, and AbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen.<ref>Template:Cite news</ref>

In September 2020, Amgen and Eli Lilly and Company announced a global manufacturing collaboration for COVID-19 antibody therapies.<ref>Template:Cite news</ref>

In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (including immunotherapy and/or chemotherapy).<ref>Template:Cite news</ref> Amgen, the Global Coalition for Adaptive Research, and Eisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19.<ref>Template:Cite news</ref>

In November 2020, Amgen, Takeda, and UCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19.<ref>Template:Cite news</ref> Amgen also announced that it would terminate its collaboration with Cytokinetics and transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.<ref>Template:Cite news</ref> Amgen and AstraZeneca announced positive topline results from a Phase 3 trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma.<ref>Template:Cite news</ref>

In December 2020, the FDA granted breakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation.<ref>Template:Cite news</ref> Also in December 2020, the FDA approved Riabni (rituximab-arrx), a biosimilar to Rituxan.<ref name="Riabni approval">Template:Cite news</ref><ref>Template:Cite press release</ref>

In April 2021, the company acquired Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion.<ref>Template:Cite press release</ref><ref>Template:Cite news</ref><ref>Template:Cite news</ref><ref>Template:Cite news</ref>

In the March 2021, Amgen acquired Rodeo Therapeutics for $720 million.<ref>Template:Cite web</ref><ref>Template:Cite press release</ref>

In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation.<ref>Template:Cite news</ref> Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe<ref>Template:Cite news</ref> and Japan.<ref>Template:Cite news</ref> The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer.<ref name="Lumakras approval">Template:Cite news</ref>

In June 2021, Amgen and Kyowa Kirin announced joint plans to develop and commercialize a treatment for atopic dermatitis.<ref>Template:Cite news</ref> In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> Amgen began construction on a new biomanufacturing plant in New Albany, Ohio, in November.<ref>Template:Cite news</ref> In December, the FDA approved Amgen and AstraZeneca's Tezspire (tezepelumab) for severe asthma.<ref name="Dunleavy">Template:Cite news</ref> The FDA also approved Amgen's Otezla for adults with plaque psoriasis of any severity level.<ref>Template:Cite news</ref>

Amgen announced a research collaboration in January 2022 with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> The company also launched a multi-target collaboration with Arrakis Therapeutics to identify novel targeted RNA degrader therapeutics.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> Also in February, Amgen issued its first green bond to fund various environmentally friendly initiatives across the company.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> The company broke ground on a new manufacturing facility in Holly Springs, North Carolina, in March.<ref>Template:Cite news</ref><ref>Template:Cite news</ref>

In September 2022, data from a late-stage study showed the company's cancer pill Lumakras (sotorasib) beating out chemotherapy. This was the first approved drug in the set of treatments that target KRAS, among the most common generic mutations found in cancers. The drug was approved in 2021 with a list price of $17,900 per month.<ref>Template:Cite news</ref>

In October 2022, the company acquired ChemoCentryx, the maker of Tavneos—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associated vasculitis, for $3.7 billion in an all-cash deal.<ref>Template:Cite news</ref><ref>Template:Cite press release</ref><ref>Template:Cite news</ref>

In October 2023, Amgen acquired Horizon Therapeutics, specializing in drugs for rare diseases, for $27.8 billion.<ref>Template:Cite news</ref><ref>Template:Cite news</ref>

In November 2023, Amgen announced plans to use artificial intelligence in partnership with Amazon Web Services to help discover and create medicines and use the Amazon SageMaker machine learning service to help with the manufacturing process.<ref>Template:Cite press release</ref>

In March 2025, data for the drug Tezspire (tezepelumab), showed the best results for treating chronic rhinosinusitis with nasal polyps.<ref>Template:Cite news</ref>

Also in March 2025, Amgen announced the start of two late-stage trials for MariTide, an anti-obesity medication candidate.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> In June 2025, the company noted that it had to reduce the dosage of the drug to avoid side effects such as vomiting.<ref>Template:Cite news</ref> However, patients that continued to take the drug lost approximately 20% of their body weight.<ref>Template:Cite news</ref>

In April 2025, the company announced a $900 million expansion of its facility in New Albany, Ohio.<ref>Template:Cite news</ref> In September 2025, it announced plans to build a $600 million research center in Thousand Oaks, California.<ref>Template:Cite news</ref>

Acquisition history

Template:Hidden start Template:Tree list

Template:Tree list/end Template:Hidden end

Corporate affairs

Sponsorships

In December 2023, Amgen became the title sponsor of the Irish Open in golf, renaming it the Amgen Irish Open.<ref>Template:Cite news</ref>

Philanthropy

In October 2017, the Amgen Foundation pledged $3 million to Khan Academy to support the development of free online biology lessons.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> In July 2020, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning.<ref>Template:Cite news</ref><ref>Template:Cite news</ref>

In January 2020, the Amgen Foundation and Harvard University debuted LabXchange, a free online science education platform.<ref>Template:Cite news</ref><ref>Template:Cite news</ref> Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March.<ref>Template:Cite news</ref>

In November 2021, Amgen awarded a $2 million grant to the CDC Foundation to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for cancer treatments.<ref>Template:Cite web</ref>

Politics

The company spends approximately $10 million per year on lobbying in the United States. Political contributions have mostly been to individuals and organizations associated with the Democratic Party.<ref>Template:Cite web</ref>

Products

Amgen's approved drugs or therapeutic biologicals include:

Products developed and then sold

In December 2012, Amgen plead guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaint related to improper marketing of anemia drug Aranesp. According to the United States Department of Justice, Amgen sold the drug for off-label uses at dosages that the FDA had rejected or never approved.<ref>Template:Cite news</ref><ref>Template:Cite press release</ref>

In May 2025, a jury ruled that Amgen owes Regeneron $406 million for engaging in anticompetitive practices to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's Praluent.<ref>Template:Cite news</ref>

See also

Template:Portal

References

Template:Reflist

Template:Commons category

Template:Finance links

Template:Pharmaceutical companies of the United States Template:Dow Jones Industrial Average companies Template:NASDAQ-100 Template:Authority control

Retrieved from "https://wiki.sarg.dev/index.php?title=Amgen&oldid=555029"